Selected aspects of human pathology, clinical oncology and epidem

Selected aspects of human pathology, clinical oncology and epidemiology. Faculty of Medicine, Oslo 2005. 34. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998, 82: 2256–2261.PubMedCrossRef 35. Neves AF, Araújo TG, Biase WK, Meola J, Alcântara TM, Freitas DG, Goulart

LR: Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Clin Biochem 2008, 41: 1191–1198.PubMedCrossRef 36. Balk SP, Ko YJ, Bubley GJ: Biology of Prostate-specific antigen. Journal of Clinical Oncology 2003, 21: 383–391.PubMedCrossRef 37. PARP inhibitor Colombatti M, Grasso S, Porzia A, Fracasso G, Scupoli MT, Cingarlini S, Poffe O, Naim HY, Heine M, Tridente G, Mainiero F, Ramarli D: The Prostate Specific Membrane Antigen

Regulates the Expression of IL-6 and CCL5 in Prostate Tumour Cells by Activating the MAPK Pathways. Plos One 2009, 4: e4608.PubMedCrossRef 38. Paliouras M, Diamandis EP: An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines. Biol Chem 2008, 389: 773–780.PubMedCrossRef 39. Serda RE, Bisoffi M, Thompson TA, Ji M, Omdahl JL, Sillerud LO: 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells. Prostate 2008, 68: 773–783.PubMedCrossRef 40. Kuroda K, Liu H, Kim S, Guo M, Navarro V, STI571 chemical structure Bander NH: Docetaxel down-regulates the expression of androgen receptor and prostate-specific Selleckchem GSI-IX antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 2009, 69: 1579–1585.PubMedCrossRef 41. Denmeade

SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT: Dissociation between androgen responsiveness for malignant growth vs expression of prostate specific differentiation Urease markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 2003, 54: 249–257.PubMedCrossRef 42. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996, 48: 326–334.PubMedCrossRef 43. Gustavsson H, Welén K, Damber JE: Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 2005, 62: 364–373.PubMedCrossRef 44. Tsui P, Rubenstein M, Guinan P: Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesis. J Biomed Biotechnol 2005, 2005: 287–290.PubMedCrossRef 45. Puhr M, Santer FR, Neuwirt H, Marcias G, Hobisch A, Culig Z: SOCS-3 antagonises the proliferative and migratory effects of FGF-1 2 in prostate cancer by inhibition of p44/p42 MAPK signaling. Endocr Relat Cancer 2010, 17: 525–53.

Methods Mol Biol 2007, 408:93–108 PubMedCrossRef 78 Laing C, Buc

Methods Mol Biol 2007, 408:93–108.PubMedCrossRef 78. Laing C, Buchanan C, Taboada EN, Zhang Y, Kropinski A, this website Villegas A, Thomas JE, Gannon VP: Pan-genome sequence analysis using Panseq: an online tool for the rapid analysis of core and accessory genomic regions. BMC Bioinforma 2010, 11:461.CrossRef 79. Gelfand Y, Rodriguez A, Benson G: TRDB–the

Tandem Repeats Database. Nucleic Acids Res 2007,35(1–2):D80-D87.PubMedCrossRef 80. Zhang Z, Schwartz S, Wagner L, Miller W: A greedy algorithm for aligning DNA sequences. J Comput Biol 2000,7(1–2):203–214.PubMedCrossRef 81. Sonnhammer EL, Durbin R: A NVP-BGJ398 order dot-matrix program with dynamic threshold control Selleck LY2874455 suited for genomic DNA and protein sequence analysis. Gene 1995,167(1–2):GC1-GC10.PubMedCrossRef 82. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997,25(17):3389–3402.PubMedCrossRef

83. Wu J, Xie J: Hidden Markov model and its applications in motif findings. Methods Mol Biol 2010,620(2010):405–416.PubMedCrossRef 84. Finn RD, Mistry J, Tate J, Coggill P, Heger A, Pollington JE, Gavin OL, Gunasekaran P, Ceric G, Forslund K, et al.: The Pfam protein families database. Nucleic Acids Res 2010,38(Database issue):D211-D222.PubMedCrossRef 85. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, et al.: Clustal W and Clustal X version 2.0. Bioinformatics

2007,23(21):2947–2948.PubMedCrossRef Aurora Kinase 86. Huson DH, Richter DC, Rausch C, Dezulian T, Franz M, Rupp R: Dendroscope: an interactive viewer for large phylogenetic trees. BMC Bioinformatics 2007, 8:460.PubMedCrossRef 87. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ: Jalview Version 2–a multiple sequence alignment editor and analysis workbench. Bioinformatics 2009,25(9):1189–1191.PubMedCrossRef Authors’ contributions VP performed the genome analyses, carried out the phospholipase assays, and was the primary author of this study. LBD, DMK, and LX prepared the ureaplasma samples, and consulted with the design of the sequencing study and analyses. JL, GHC and JIG did sequencing and analyses of the mba genes prior to the genome sequencing that influenced the analyses done on the genomes. SY, SS, JI, and JIG carried out some of the bioinformatics analyses and genome annotation. BAM coordinated the sequencing and conducted the assembly of the 14 ATCC type strains. GHC, KBW, and JIG conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

hispaniensis FSC454 and/or W persica FSC845 as well as low score

hispaniensis FSC454 and/or W. persica FSC845 as well as low scores in clade 1. Only three (11-fopA-in, 14-Ft-M19 and 15-Ft-M19) out of the fifteen markers consistently differentiated

clade 1 from the rest of the Francisella genus. The marker 10-fopA was the only marker completely specific for clade 2 and only marker 24-lpnB was specific for F. noatunensis. Both of these exhibited lower specificity for F. noatunensis subsp. orientalis genomes. Several markers displayed complex amplification patterns. Seven markers (Poziotinib price 02-16S-Itr-23S, 06-atpA, 09-fopA, 29-pgm, 32-rpoA, 33-rpoB, 34-sdhA) had high scores in one or more species or subspecies, e.g. the marker 09-fopA had a low score in all included strains except in F. hispaniensis FSC454 and W. persica

FSC845. Similar results were observed for 02-16S-Itr-23S, 29-pgm, 33-rpoB and 34-sdhA. Four detection markers (16-FTT0376, 17-FTT0523, AZD3965 molecular weight 20-ISFtu2 and 28-pdpD) had missing data (i.e. the sequence could not be found in the genome) for all clade 2 isolates plus W. persica. The markers 16-FTT0376 and 17-FTT0523 had missing sequences for F. hispaniensis and F. tularensis subsp. novicida, except the isolates FSC159 and GA993549, respectively. The marker 21-ISFtu2 had missing sequences as well as mismatches in almost all subspecies represented. A summary of the DNA-marker evaluation can be found in Table 3, and more detailed selleck information, including earlier published results for each marker, can be found in Additional file 1. Table 3 Summary of estimated amplification performance of primer pairs representing

published DNA-based markers targeting Francisella Estimated amplification performance Marker id Amplifies the entire genus 01-16S, 03-16S-Itr-23S, 04-16S-Itr-23S, 08-fabH, 18-groEL, 23-lpnAa, 25-mdh, 30-prfb and 35-tpiA. Amplifies clade 1 but not clade 2 05-aroA, 07-dnaA, 11-fopA-inaa, 12-fopA-outa, 13-fopAa, 14-FTM19b, 15-FTM19, 19-iglCac, 22-lpnAa, 26-mutS, 27-parCc, 31-putA, 36-tpiA, 37-trpE and 38-uup.  Amplifies clade 1 but no other Francisella species. 11-fopA-ina, 14-FtM19 and 15-FtM19a  Amplifies clade 1 as well as F. hispaniensis and W. persica 05-aroA, 07-dnaA, 12-fopA-outa, 27-parCc and 36-tpiA.  Amplifies clade 1 as well as F. hispaniensis 13-fopAa, 19-iglCc, 22-lpnA, 31-putA, 37-trpE and 38-uup. Phosphoprotein phosphatase  Amplifies clade 1 as well as W. persica 26-mutS Amplifies clade 2 but not clade 1 10-fopA Amplifies noatunensis but not the other species 24-lpnB Amplifies all isolates except some certain species. 02-16S-Itr-23S, 06-atpA, 09-fopA, 29-pgm, 32-rpoA, 33-rpoB and 34-sdhA.  Amplifies all except F. hispaniensis and W. persica 09-fopA  Amplifies all except F. hispaniensis 33-rpoB  Amplifies all except F. tularensis, W. persica and F. hispaniensis 34-sdhA  Amplifies all except W. persica 02-16S-Itr-23S, 29-pgm  Amplifies all except F. noatunensis subsp. orientalis 06-atpA  Amplifies all except F.

Vertical black lines indicate cos and attP sites respectively Re

Vertical black lines indicate cos and attP sites respectively. Red arrows indicate tRNA genes. Pseudogenes are marked with PF-3084014 a black asterisk. Below the scale, arrows represent homologous proteins of bacteriophages and prophages from

different hosts with S. flexneri, E. coli and Salmonella framed within a green, red or blue box, respectively. Homologs between SfI and other phages/prophages are shown in different colors with color coding corresponding to level of homology at amino acid level, with red of 100% identity and blue of > =50% identity. Phage SfI has a very narrow host range Host specificity of serotype-converting bacteriophages has long been recognized, which results in the specific lytic spectrum and serotype conversion of S. flexneri in nature [20]. The recognition between the O-antigen of host bacterium and the tail component of a phage is the key mechanism of host specificity [20]. To determine the host range of SfI, 132 S. flexneri Selleck Vorinostat strains of 12 serotypes (1a, 1b, 2a, 2b, 3a, 3b, 4a,

4b, 5a, Y, X and Xv) were tested following the methods described in the Methods. Apart from 10 serotype Y strains, which were all converted to serotype 1a as expected, the 24 serotype X strains tested were also lysogenized, and converted to a newly named serotype 1d [16]. The serotype 1d strains were serologically characterized as reacting with both serotype 1 specific I typing sera and serotype X specific 7;8 grouping sera [16]. Interestingly, such a serotype has already appeared in natural infections in Anhui and Henan selleck kinase inhibitor provinces, China [21]. Except for serotypes Y and X, the other serotypes could not be lysogenized by phage SfI. A possible explanation for the host range restriction of phage SfI is phage immunity due to modification of the O-antigen as phage receptors [22]. SfI uses a site-specific mechanism for DNA packaging and has the same attP core sequence as SfII, SfIV, SfV and SfX Restriction enzyme analysis revealed that phage SfI has a linear but not circular Buspirone HCl genome (data not shown). Genomic comparison found that the

SfI prophage genome has similar packaging genes to that of phage SfV; and the fragments adjacent to them were also highly similar to the cohesive end site (cos) of phage SfV [9], with only one base difference at the 5′ end (T versus A). These data suggest that SfI may use the same site-specific mechanism as SfV for packaging. Direct sequencing of the putative termini of the SfI genome extracted from free phage particles and comparison of the corresponding regions with the SfI prophage genome in strain 019 revealed a 10 nucleotide (5′- TGCCCGCCCC -3′) gap in the SfI phage genome. Therefore, we conclude that SfI uses a cos mechanism for DNA packaging as postulated for phage SfV [9], and does not use a head full mechanism (pac) as for phage Sf6 and SfX [10, 12].

For e

For example, dioxins in breast milk were linked to a lower FEV1/FVC ratio in Danish children (mean age 8.2 years), but the sample size was only 29 (ten Tusscher et al. 2001). In a meta-analysis involving 53,879 children, parental smoking was linked to respiratory symptoms, but relative risks were generally low (around 1.15) (Pattenden et al. 2006). In a subsample of 22,712 of these children with valid lung function data, maternal smoking during pregnancy was linked to a 1% decrease in FEV1 and essentially no change in FVC (Moshammer et al. 2006). In a longitudinal study

on outdoor air pollution in southern California, the mean difference in FEV1 growth from age 10 to 18 between the most exposed city (PM10 = 68 μg/m3) and the least exposed #SN-38 manufacturer randurls[1|1|,|CHEM1|]# city (PM10 = 17 μg/m3) was 82 ml. Similar effects were seen for PM2.5, NO2, and acid vapor (Gauderman et al. 2004). In the current study, we observed 4-fold larger FEV1 decrements (335 ml) nearly 40 years after high arsenic exposures ended. Conclusions This study provides the first evidence that in utero and childhood exposure to arsenic in drinking water is associated with long-term lung function deficits and shortness of breath in humans. The magnitude of the decrease in find more both FEV1 and FVC suggests that early-life arsenic exposure could have effects similar to smoking throughout adulthood and greater effects than secondhand

smoke or air pollution. Nonetheless, certain potential biases—especially those related to non-random selection of subjects—were not controlled for and cannot be excluded. These results should be confirmed in a larger study with participants who are representative of the source population. Etomidate A larger study could also investigate the effects of lower exposures as well as effect modification and confounding by factors such as diet, occupational exposures, smoking, and gender. The public

health importance lies in the enormous morbidity and mortality associated with respiratory effects of this magnitude, the millions of children with high exposures worldwide, and the need to incorporate data on early-life susceptibility into environmental policy. Acknowledgments We thank the Rodriguez-Pereira family and Sandra Cortes for their support. This study was funded by the Northern California Center for Occupational and Environmental Health, the University of California, Berkeley, Center for Global Public Health, and the U.S. National Institute of Health grants P42-ES04705 and R01-ES017463. The authors declare they have no competing financial interests. Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. References ATS (American Thoracic Society) (1995) Standardization of spirometry, 1994 update.

Recent studies describing outbreaks of Cmm in Europe and Asia [5–

Recent studies describing outbreaks of Cmm in Europe and Asia [5–8] have shed some light

on this issue. In Italy a clonal population of Cmm was responsible eFT508 solubility dmso for the outbreak in 2007 [9]. A high homogeneity was also observed among strains isolated from 2002 to 2007 in Canary Islands suggesting a single introduction of the pathogen as a source of infection [6]. Primary infections in many countries were attributed to the introductions of contaminated tomato seeds and/or seedlings [7, 10]. These findings indicate that seeds play an important role in long-distance spread of the pathogen. A direct link between tomato cultivar, year or place of isolation and Cmm type mostly could not be recognized [6, 8, 9] except the outbreak in 2001 in Turkey where bacterial canker was detected only on one tomato cultivar ‘Target’ [11]. Interestingly, in Israel and Serbia Cmm strains showing the same haplotypes were repeatedly isolated from the same locations during several subsequent years [7, 10]. Reoccurring outbreaks suggest that despite intensified efforts for eradication, reliable control of this disease remains an unattainable goal. The limited progress in improving its management is mainly due to the sporadic nature of the disease outbreaks and to limited and scattered epidemiological data. Therefore, access

to an accurate, efficient and cost-effective CH5424802 strain typing technique could be very useful. Bacterial typing techniques are applied to quickly and reliably differentiate closely related strains in an epidemiological survey, to determinate the relatedness among the strains and to track their BIRB 796 concentration origin and pathways of spread. Over the past decades a variety of different typing methods have been developed to generate strain-specific patterns. They are also applied for comprehensive investigation of bacterial population structure and dynamics. A range

of methods has already been applied to study the diversity of Clavibacter, particularly to investigate Cmm strains. Rep-PCR (repetitive-element-based PCR), a relatively easy and fast technique, was shown to be of moderate utility [8], mainly because of the lack of a database and the rather low discriminatory power needed to study closely Ureohydrolase related strains. Moreover, rep-PCR is mostly not portable between different laboratories [12]. PFGE (pulsed-field gel electrophoresis of macro-restricted bacterial DNA), one of the oldest techniques used in epidemiology, is labor intensive and expensive but is still used as a gold standard in typing of some bacterial species [10, 13]. PFGE was applied to study the diversity of Cmm strains from outbreaks in Serbia [7] and in Israel [10] where the results of PFGE showed similar resolution of those obtained by gene sequence analysis and rep-PCR, respectively.

J Clin Endocrinol Metab 97:3097–3106PubMedCrossRef 6 Ito M, Naka

J Clin Endocrinol Metab 97:3097–3106PubMedCrossRef 6. Ito M, Nakata T, Nishida A, Uetani M (2011) Age-related changes in bone density, geometry and biomechanical properties of the proximal femur: CT-based 3D hip structure analysis in normal postmenopausal women. Bone 48:627–630PubMedCrossRef 7. Ito M, Wakao N, Hida T, Matsui Y, Abe Y, Aoyagi K, Uetani M, Harada A (2010) Analysis of hip geometry by clinical CT for the assessment of hip fracture risk in elderly Japanese women. selleck chemicals Bone 46:453–457PubMedCrossRef

8. Borggrefe J, Graeff C, Nickelsen TN, Marin F, Gluer CC (2010) Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. JBMR 25:472–481CrossRef 9. Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ (2005) Effects of teriparatide [rhPTH(1–34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 36:948–958PubMedCrossRef 10. Ito M, Nakamura T, Fukunaga M, Shiraki M, Matsumoto T (2011) Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT. Bone 49:328–334PubMedCrossRef 11. Black DM, Greenspan SL, Ensrud KE, selleck kinase inhibitor Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ, for the PaTH Study Investigators

(2003) The effects MEK inhibitor of parathyroid hormone and alendronate alone or in

combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215PubMedCrossRef 12. Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL, Black DM (2008) Femoral bone strength and its relation to cortical and trabecular changes after BCKDHB treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res 23:1974–1982PubMedCrossRef 13. Macdonald HM, Nishiyama KK, Hanley DA, Boyd SK (2011) Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. Osteoporos Int 22:357–362PubMedCrossRef 14. Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB (2007) Effects of a one-month treatment with PTH(1–34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 22:495–502PubMedCrossRef 15. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL (2003) Effects of teriparatide [recombinant human parathyroid hormone (1–34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539–543PubMedCrossRef 16. Seeman E (2002) Pathogenesis of bone fragility in women and men. Lancet 359:1841–1850PubMedCrossRef 17. Seeman E (2003) Periosteal bone formation-a neglected determinant of bone strength. N Engl J Med 349:320–323PubMedCrossRef 18.

monocytogenes pAKB-lmo1438 compared with L monocytogenes pAKB, w

monocytogenes pAKB-lmo1438 compared with L. monocytogenes pAKB, when both were cultured in the presence of nisin, indicated that this phenomenon is a consequence of PBP3 overexpression. Figure 2 Pattern of PBPs in L. monocytogenes check details strain overexpressing lmo1438. Membrane proteins (200 μg of total protein) of L. monocytogenes pAKB (lane 1) and L. monocytogenes pAKB-lmo1438 (lane 2) were incubated with [3H]benzylpenicillin

at a saturating concentration of 5 μg/ml and the radiolabeled PBPs were separated by SDS-PAGE and detected by fluorography. The PBP corresponding to each band is indicated on the right. Table 1 Relative selleck screening library amounts of PBPs in recombinant L.monocytogenes strains Protein Amount of PBP protein a   L. monocytogenes pAKB L. monocytogenes pAKB- lmo1438 PBP1 4.48 (± 0.45) 4.21 (± 0.81) PBP2 1 b 0.96 (± 0.08) PBP3 1.66 (± 0.15) 5.78 (± 0.47) c PBP4 1.67 (± 0.05) 3.2 (± 0.34) c PBP5 12.05 (± 0.42) 12.01 (± 1.03) a Average results of densitometric analysis of three independent fluorograms. b Values were normalized to the band intensity of PBP2

from L. monocytogenes pAKB, which was assigned the value of 1. c Indicates band with intensity significantly different (P < 0.05; acc. to Student's t-test) from the corresponding band of the control strain. Effect of PBP3 overproduction on growth and cell morphology of L. monocytogenes Since mutation of the lmo1438 gene did not cause Selleckchem OSI906 any changes in the growth and cell morphology of L. monocytogenes, the physiological role of PBP3 is unclear. To better understand the cellular function of PBP3, the effect of increased production of this protein on the growth and morphology of L. monocytogenes was examined. The growth rate of the strain overproducing

PBP3 was visibly retarded during the exponential phase of growth, when the doubling time of L. monocytogenes pAKB-lmo1438 was 116 min compared to 62 min for L. monocytogenes pAKB. However, in the stationary phase of growth the culture of L. monocytogenes pAKB-lmo1438 reached a higher OD600 value compared to the control Protein tyrosine phosphatase strain, which correlated with a significantly higher number of viable bacteria in this phase of growth (Figure 3A). Figure 3 Effect of overproduction of PBP3 on growth and morphology of L. monocytogenes. (A) Growth of L. monocytogenes pAKB (○) and L. monocytogenes pAKB-lmo1438 (•) incubated in BHI broth at 37°C following nisin induction, determined by serial dilution of the cultures and enumeration of viable cells on BHI agar. Error bars represent standard deviation from the means of three independent experiments, each performed in triplicate. (B) SEM images of L. monocytogenes pAKB (Lm pAKB) and L. monocytogenes pAKB-lmo1438 (Lm pAKB-lmo1438) cells grown overnight in BHI broth at 37°C following nisin induction. The mean cell lengths (± SD), determined by measuring 100 cells of each strain, are shown in parentheses. Bar = 2 μm. Analysis of cell morphology by scanning electron microscopy revealed that L. monocytogenes pAKB and L.

Mutagenesis 1:91–97PubMedCrossRef 92 Klausner RD, Patel MD, O’Sh

Mutagenesis 1:91–97PubMedCrossRef 92. Klausner RD, Patel MD, O’Shea JJ et al (1987) Phosphorylation of

the T cell antigen receptor: multiple signal transduction DMXAA research buy pathways. J Cell Physiol Suppl 5:49–51PubMedCrossRef 93. Castagna M (1987) Phorbol esters as signal transducers and tumor promoters. Biol Cell 59:3–13PubMed 94. Bockenstedt LK, Goldsmith MA, Koretzky GA et al (1987) The activation of T lymphocytes. Rheum Dis Clin North Am 13:411–430PubMed 95. Lockwood AH, Murphy SK, Se B et al (1987) Cellular signal transduction and the reversal of malignancy. J Cell Biochem 33:237–255PubMedCrossRef 96. Linch DC, Wallace DL, O’Flynn K (1987) Signal transduction in human T lymphocytes. Immunol Rev 95:137–159PubMedCrossRef 97. Bourne HR (1988) Signals past, present, and future. Cold Spring Harb Symp Quant Biol 53:1019–1031PubMed 98. Hunter T, Angel P, Boyle WJ et al (1988) Targets for signal-transducing protein kinases. Cold Spring Harb Symp Quant Biol 53:131–142PubMed 99. Goldsmith MA, Weiss A (1988) Generation and analysis of a T-lymphocyte somatic mutant for studying molecular aspects of signal transduction by the antigen receptor. Ann N Y Acad Sci 546:91–103PubMedCrossRef 100. Weinstein IB (1988) Strategies for inhibiting multistage carcinogenesis

based on signal transduction MRT67307 manufacturer pathways. Mutat Res 202:413–420PubMed 101. Harris AL, Nicholson S (1988) Epidermal IWP-2 solubility dmso Growth factor receptors in human breast cancer. Cancer Treat Res 40:93–118PubMed 102. Liotta LA, Stracke ML (1988) Tumor invasion and metastases: biochemical mechanisms. Cancer Treat Res 40:223–238PubMed 103. Dillon SB, Verghese MW, Snyderman R (1988) Signal transduction in cells following binding of chemoattractants to membrane

receptors. Virchows Arch B Cell Pathol Incl Mol Pathol 55:65–80PubMed 104. Blumberg DD, Comer JF, Higinbotham KG (1988) A Ca2+-dependent signal transduction system participates Amino acid in coupling expression of some cAMP-dependent prespore genes to the cell surface receptor. Dev Genet 9:359–369PubMedCrossRef 105. Yuspa SH, Hennings H, Tucker RW et al (1988) Signal transduction for proliferation and differentiation in keratinocytes. Ann N Y Acad Sci 548:191–196PubMedCrossRef 106. Roskelley CD, Desprez PY, Bissell MJ (1994) Extracellular matrix-dependent tissue-specific gene expression in mammary epithelial cells requires both physical and biochemical signal transduction. Proc Natl Acad Sci U S A 91:12378–12382PubMedCrossRef 107. Boudreau N, Myers C, Bissell MJ (1995) From laminin to lamin: regulation of tissue-specific gene expression by the ECM. Trends Cell Biol 5:1–4PubMedCrossRef 108. Mazure NM, Chen EY, Yeh P et al (1996) Oncogenic Transformation and Hypoxia Synergistically Act to Modulate Vascular Endothelial Growth Factor Expression. Cancer Research 56:3436–3440PubMed 109. Halachmi E, Witz IP (1989) Differential tumorigenicity of 3T3 cells transformed in vitro with polyoma virus and in vivo selection for high tumorigenicity. Cancer Res 49:2383–2389PubMed 110.

Depending on the cell system investigated, As2O3-induced cell dea

Depending on the cell system investigated, As2O3-induced cell death has been associated with caspase-dependent apoptosis, as well as caspase-independent death pathways [16–18]. In this study, the combination learn more of As2O3 and DDP increased caspase-3 expression, which indicates that caspase might be involved in apoptosis induced by As2O3 or DDP. However,

the combination of As2O3 and DDP did not affect caspase-3 expression compared with cells treated with a single agent, which suggests that the synergistic effects are more likely to be caspase-independent. This study showed caspase-independent death pathways that involved Bcl-2, Bax, and clusterin were the primary mechanism by which As2O3 exerts synergistic effects with DDP on NSCLC cells. In conclusion, As2O3 exerted synergistic effects with DDP on lung cancer cells. The proliferation inhibition might be partly due to the induction of apoptosis. Based on our study, As2O3 may be a promising agent in the treatment of lung cancer, although further in vitro and in vivo studies are necessary to elucidate the mechanism by which As2O3 induces apoptosis. Acknowledgements

We are grateful to Professor Stefan Glück (Division of Hematology/Oncology, UMSylvester Comprehensive Cancer Center, SBI-0206965 mouse University of Miami, FL) for the review of our manuscript. This work was sponsored in part by a National Natural Science Foundation of China Grant 30600756 (to H.L.), the Shanghai Rising-Star Program (A type 07QA14011, to H.L), and a Youth Foundation Grant 05L-A-11 from Fudan University (to H.L.). References 1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1998. CA Cancer J Clin 1998, 48 (1) : 6–29.CrossRefPubMed 2. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio

A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. before N Engl J Med 1998, 339 (19) : 1341–1348.CrossRefPubMed 3. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH Jr: Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998, 90 (2) : 124–133.CrossRefPubMed 4. Look AT: Arsenic and apoptosis in the treatment of acute promyelocytic leukemia. J Natl Cancer Inst 1998, 90 (2) : 86–88.CrossRefPubMed 5. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z: Use of arsenic trioxide (As 2 O 3 ) in the treatment of acute promyelocytic leukemia (APL): I. As 2 O 3 exerts dose-dependent dual effects on APL cells. Blood 1997, 89 (9) : 3345–3353.PubMed 6.